EA201691109A1 - Химерные и гибридные полипептиды фактора viii-fc и способы их применения - Google Patents

Химерные и гибридные полипептиды фактора viii-fc и способы их применения

Info

Publication number
EA201691109A1
EA201691109A1 EA201691109A EA201691109A EA201691109A1 EA 201691109 A1 EA201691109 A1 EA 201691109A1 EA 201691109 A EA201691109 A EA 201691109A EA 201691109 A EA201691109 A EA 201691109A EA 201691109 A1 EA201691109 A1 EA 201691109A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
hybrid polypeptides
viii
chemeric
factor
Prior art date
Application number
EA201691109A
Other languages
English (en)
Other versions
EA038618B1 (ru
Inventor
Дженнифер А. Дьюмонт
Сьюзен Лоу
Алан Дж. Битонти
Гленн Пирс
Элвин Люк
Хайянь Цзян
Байрон Маккинни
Мэтт Оттмер
Юрг Зоммер
Карен Ньюджент
Лиан Ли
Роберт Питерс
Original Assignee
Байоджен Хемофилия Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Хемофилия Инк. filed Critical Байоджен Хемофилия Инк.
Publication of EA201691109A1 publication Critical patent/EA201691109A1/ru
Publication of EA038618B1 publication Critical patent/EA038618B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение направлено на создание способов введения фактора VIII; способов введения химерных и гибридных полипептидов, содержащих фактор VIII; химерных и гибридных полипептидов, содержащих фактор VIII; полинуклеотидов, кодирующих такие химерные и гибридные полипептиды; клеток, содержащих такие полинуклеотиды; и способов получения таких химерных и гибридных полипептидов с применением таких клеток.
EA201691109A 2009-12-06 2010-12-06 Химерные и гибридные полипептиды фактора viii-fc и способы их применения EA038618B1 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US26707009P 2009-12-06 2009-12-06
US28505409P 2009-12-09 2009-12-09
US30159210P 2010-02-04 2010-02-04
US36306510P 2010-07-09 2010-07-09
US37311310P 2010-08-12 2010-08-12
US41092910P 2010-11-07 2010-11-07
US41967610P 2010-12-03 2010-12-03

Publications (2)

Publication Number Publication Date
EA201691109A1 true EA201691109A1 (ru) 2017-01-30
EA038618B1 EA038618B1 (ru) 2021-09-23

Family

ID=44115536

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201691109A EA038618B1 (ru) 2009-12-06 2010-12-06 Химерные и гибридные полипептиды фактора viii-fc и способы их применения
EA201290443A EA025416B1 (ru) 2009-12-06 2010-12-06 Способ предотвращения или лечения эпизодов кровотечений с использованием химерного полипептида фактора viii длительного действия

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201290443A EA025416B1 (ru) 2009-12-06 2010-12-06 Способ предотвращения или лечения эпизодов кровотечений с использованием химерного полипептида фактора viii длительного действия

Country Status (30)

Country Link
US (5) US9050318B2 (ru)
EP (4) EP2506868B1 (ru)
JP (7) JP5903048B2 (ru)
KR (1) KR101770849B1 (ru)
CN (1) CN102791285A (ru)
AU (5) AU2010325787B2 (ru)
BR (1) BR112012013502A2 (ru)
CA (2) CA3121739A1 (ru)
CO (1) CO6561782A2 (ru)
CY (2) CY1119919T1 (ru)
DK (1) DK2506868T3 (ru)
EA (2) EA038618B1 (ru)
ES (2) ES2880038T3 (ru)
HK (1) HK1253887A1 (ru)
HR (2) HRP20180135T1 (ru)
HU (1) HUE036233T2 (ru)
IL (2) IL220204B (ru)
LT (1) LT2506868T (ru)
ME (1) ME02964B (ru)
MX (2) MX336830B (ru)
MY (1) MY159135A (ru)
NO (1) NO2506868T3 (ru)
NZ (2) NZ703153A (ru)
PL (2) PL2506868T3 (ru)
PT (2) PT3326643T (ru)
RS (1) RS56957B1 (ru)
SG (3) SG10201408049SA (ru)
SI (1) SI2506868T1 (ru)
WO (1) WO2011069164A2 (ru)
ZA (1) ZA201204874B (ru)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
RS56957B1 (sr) 2009-12-06 2018-05-31 Bioverativ Therapeutics Inc Himerni i hibridni polipeptidi faktora viii-fc, i postupci za njihovu upotrebu
TW201217526A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Chimeric clotting factors
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3431485B1 (en) 2010-10-01 2020-12-30 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
EP2635310A2 (en) * 2010-11-05 2013-09-11 Rinat Neuroscience Corp. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
SI2717898T1 (sl) 2011-06-10 2019-07-31 Bioverativ Therapeutics Inc. Spojine prokoagulantov in metode za njihovo uporabo
TWI687226B (zh) * 2011-07-08 2020-03-11 美商百歐維拉提夫治療公司 因子ｖｉｉｉ嵌合及雜交多肽，及其使用方法
US10656167B2 (en) 2011-07-25 2020-05-19 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AU2012318752B2 (en) 2011-10-03 2017-08-31 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
ES2899848T3 (es) 2012-01-12 2022-03-15 Bioverativ Therapeutics Inc Reducción de la inmunogenicidad contra el factor VIII en individuos sometidos a una terapia con factor VIII
US11370827B2 (en) * 2012-01-12 2022-06-28 Bioverativ Therapeutics Inc. Chimeric factor VIII polypeptides and uses thereof
DK2822577T3 (en) 2012-02-15 2019-04-01 Bioverativ Therapeutics Inc RECOMBINANT FACTOR VIII PROTEINS
EP3564260B1 (en) * 2012-02-15 2022-10-19 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
EP2833923A4 (en) 2012-04-02 2016-02-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US10317376B2 (en) 2012-04-11 2019-06-11 Bioverativ Therapeutics Inc. Methods of detecting glycosaminoglycans
WO2013185114A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
US10287564B2 (en) 2012-06-08 2019-05-14 Bioverativ Therapeutics Inc. Procoagulant compounds
EP3404105A1 (en) * 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
JP6603128B2 (ja) * 2012-07-11 2019-11-06 バイオベラティブ セラピューティクス インコーポレイテッド ＸＴＥＮおよびｖｏｎＷｉｌｌｅｂｒａｎｄ因子タンパク質を有する第ＶＩＩＩ因子の複合体、および、その使用
US10001495B2 (en) 2012-07-25 2018-06-19 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
EP2908847B1 (en) 2012-10-18 2022-03-30 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP2914293A4 (en) * 2012-10-30 2016-04-20 Biogen Ma Inc METHOD OF USE OF FVIII POLYPEPTIDE
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
US10717965B2 (en) 2013-01-10 2020-07-21 Gloriana Therapeutics, Inc. Mammalian cell culture-produced neublastin antibodies
HUE053136T2 (hu) * 2013-02-15 2021-06-28 Bioverativ Therapeutics Inc Optimizált VIII. faktor gén
US9090697B2 (en) * 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
SG11201505924TA (en) * 2013-03-15 2015-09-29 Biogen Ma Inc Factor viii polypeptide formulations
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014190305A2 (en) 2013-05-24 2014-11-27 Biogen Idec Ma Inc. Anti-gpiib/iiia antibodies or uses thereof
TW201536811A (zh) * 2013-05-31 2015-10-01 Biogen Idec Inc 嵌合ｆｖｉｉ－ｘｔｅｎ分子及其用途
AU2014287706B2 (en) * 2013-06-20 2017-10-05 Takeda Pharmaceutical Company Limited Providing a pharmacokinetic drug dosing regimen
WO2014210547A1 (en) * 2013-06-28 2014-12-31 Biogen Idec Ma Inc. Thrombin cleavable linker
IL297611A (en) * 2013-06-28 2022-12-01 Bioverativ Therapeutics Inc Binding of thrombin that degrades with castane and uses thereof
JP6521959B2 (ja) 2013-07-31 2019-05-29 ライナット ニューロサイエンス コーポレイション 操作されたポリペプチドコンジュゲート
WO2015023894A1 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Recombinant factor viii proteins
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
WO2015085276A1 (en) * 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Population pharmacokinetics tools and uses thereof
WO2015095809A1 (en) 2013-12-20 2015-06-25 Biogen Idec Ma Inc. Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
MY192481A (en) 2014-01-10 2022-08-23 Bioverativ Therapeutics Inc Factor viii chimeric proteins and uses thereof
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
WO2015148454A1 (en) * 2014-03-28 2015-10-01 Asklepios Biopharmaceutical, Inc. Optimized and modified factor viii genes for gene therapy
PL3134127T3 (pl) 2014-04-25 2020-07-27 Rinat Neuroscience Corp. Koniugaty przeciwciało-lek o dużym ładunku leku
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
EP3331608A4 (en) 2015-08-03 2019-05-01 Bioverativ Therapeutics Inc. FUSION XI FUSION PROTEINS AND METHODS OF MAKING AND USING THE SAME
US11560418B2 (en) 2015-10-20 2023-01-24 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor IX fusion proteins
HUE059941T2 (hu) 2016-02-01 2023-01-28 Bioverativ Therapeutics Inc Optimalizált VIII-as faktor gének
AU2017250570A1 (en) 2016-04-15 2018-11-15 Takeda Pharmaceutical Company Limited Method and apparatus for providing a pharmacokinetic drug dosing regiment
TW201739448A (zh) * 2016-05-06 2017-11-16 安成生物科技股份有限公司 用於治療及/或預防血液相關疾病之方法及配方
WO2017222337A1 (ko) 2016-06-24 2017-12-28 재단법인 목암생명과학연구소 Fviii 및 vwf 인자를 포함하는 키메라 단백질 및 그 용도
US11447542B2 (en) 2016-08-05 2022-09-20 Medimmune, Llc Anti-O2 antibodies and uses thereof
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
JP7160484B2 (ja) 2016-10-19 2022-10-25 メディミューン，エルエルシー 抗ｏ１抗体およびその使用
CN108239151B (zh) * 2016-12-23 2020-07-03 海门晟斯生物制药有限公司 重组单链人FVIII-Fc融合蛋白及其应用
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
CN110831613A (zh) 2017-01-31 2020-02-21 比奥维拉迪维治疗股份有限公司 因子ix融合蛋白及其制备和使用方法
MA52783A (fr) 2018-06-05 2021-04-14 Amgen Inc Modulation de la phagocytose cellulaire dépendant de l'anticorps
AU2019339895A1 (en) 2018-09-11 2021-03-11 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
WO2020086408A1 (en) 2018-10-26 2020-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A high-yield perfusion-based transient gene expression bioprocess
MX2021006648A (es) 2018-12-06 2021-07-07 Bioverativ Therapeutics Inc Uso de vectores lentivirales que expresan el factor ix.
BR112021025426A2 (pt) 2019-06-19 2022-06-21 Bioverativ Therapeutics Inc Fator recombinante viii-fc para tratamento de hemofilia e baixa densidade mineral óssea
WO2023211315A1 (en) * 2022-04-28 2023-11-02 Joint Stock Company "Biocad" Isolated nucleic acid that encodes fusion protein based on fviii-bdd and on heterologous signal peptide
CN114989307B (zh) * 2022-05-11 2023-08-01 华兰生物工程股份有限公司 一种重组人凝血因子Ⅷ-Fc融合蛋白及制备方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235881A (en) * 1978-12-04 1980-11-25 Cort Joseph H Method for producing high potency factor VIII
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
ES8801674A1 (es) 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
DE3785102T2 (de) 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5610278A (en) 1986-06-24 1997-03-11 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
CA2078721A1 (en) 1991-09-24 1993-03-25 Hiroshi Yonemura Process for preparing human coagulation factor viii protein complex
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
AU4314801A (en) 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
ES2484966T3 (es) * 2000-04-12 2014-08-12 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
EP1359936B1 (en) * 2001-02-05 2008-02-20 Novo Nordisk Health Care AG Combined use of factor vii polypeptides and factor viii polypeptides
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP1444986A1 (en) * 2003-02-07 2004-08-11 Aventis Behring GmbH Pharmaceutical preparation for the improved treatment of blood-clotting disorders
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP3552627A1 (en) * 2003-05-06 2019-10-16 Bioverativ Therapeutics Inc. Clotting factor-fc chimeric proteins to treat hemophilia
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
JP5114055B2 (ja) * 2003-06-19 2013-01-09 ジェネンテック， インク． 障害に関連する凝固の治療用組成物および方法
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
EP1824988B1 (en) 2004-11-12 2017-04-19 Bayer HealthCare LLC Site-directed modification of fviii
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1996220B2 (en) 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
EP2010222A1 (en) * 2006-03-31 2009-01-07 Baxter International Inc. Pegylated factor viii
EP2097096B1 (en) 2006-12-22 2017-05-31 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
EP2185701A4 (en) 2007-08-15 2011-03-02 Amunix Operating Inc COMPOSITIONS AND METHODS FOR ENHANCING THE PRODUCTION OF RECOMBINANT POLYPEPTIDES
AU2009219232B2 (en) * 2008-02-27 2014-02-27 Novo Nordisk A/S Conjugated Factor VIII molecules
US8800831B2 (en) 2009-08-19 2014-08-12 Larry A. Gray Multi-purpose rack and method thereof
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
CN102427823A (zh) * 2009-03-24 2012-04-25 拜耳医药保健有限公司 因子viii变体及使用方法
GB0908515D0 (en) 2009-05-18 2009-06-24 Apitope Technology Bristol Ltd Peptide
RS56957B1 (sr) 2009-12-06 2018-05-31 Bioverativ Therapeutics Inc Himerni i hibridni polipeptidi faktora viii-fc, i postupci za njihovu upotrebu
TWI687226B (zh) 2011-07-08 2020-03-11 美商百歐維拉提夫治療公司 因子ｖｉｉｉ嵌合及雜交多肽，及其使用方法
SG11201505924TA (en) * 2013-03-15 2015-09-29 Biogen Ma Inc Factor viii polypeptide formulations
JP6083911B2 (ja) 2014-12-19 2017-02-22 花王株式会社 吸収性物品

Also Published As

Publication number Publication date
CY1124888T1 (el) 2023-01-05
JP2015083608A (ja) 2015-04-30
AU2019202969A1 (en) 2019-05-16
PT3326643T (pt) 2021-07-12
AU2016213822A1 (en) 2016-09-01
MX2012006347A (es) 2012-10-03
US9241978B2 (en) 2016-01-26
BR112012013502A2 (pt) 2017-01-10
EA025416B1 (ru) 2016-12-30
ES2880038T3 (es) 2021-11-23
EA038618B1 (ru) 2021-09-23
EP2506868A4 (en) 2013-07-24
EA201290443A1 (ru) 2013-06-28
JP2022051964A (ja) 2022-04-01
KR20120129882A (ko) 2012-11-28
ZA201204874B (en) 2016-06-29
DK2506868T3 (da) 2018-01-29
MX353233B (es) 2018-01-08
RS56957B1 (sr) 2018-05-31
IL220204B (en) 2018-08-30
MY159135A (en) 2016-12-15
PL3326643T3 (pl) 2021-10-25
CA2782424A1 (en) 2011-06-09
HRP20211010T1 (hr) 2021-09-17
US20130274194A1 (en) 2013-10-17
HUE036233T2 (hu) 2018-06-28
WO2011069164A2 (en) 2011-06-09
JP2020019821A (ja) 2020-02-06
JP6385410B2 (ja) 2018-09-05
IL260769B (en) 2020-03-31
PT2506868T (pt) 2018-02-23
LT2506868T (lt) 2018-02-26
JP2017025098A (ja) 2017-02-02
JP6641340B2 (ja) 2020-02-05
AU2016213822B2 (en) 2017-08-31
CN102791285A (zh) 2012-11-21
CA2782424C (en) 2021-07-27
US9050318B2 (en) 2015-06-09
SG181130A1 (en) 2012-07-30
HRP20180135T1 (hr) 2018-04-06
CO6561782A2 (es) 2012-11-15
JP2013512678A (ja) 2013-04-18
EP2506868A2 (en) 2012-10-10
ES2659888T3 (es) 2018-03-19
AU2010325787B2 (en) 2016-05-12
HK1253887A1 (zh) 2019-07-05
AU2010325787A2 (en) 2013-06-06
AU2021202912A1 (en) 2021-06-03
US20220265780A1 (en) 2022-08-25
AU2017268648A1 (en) 2017-12-21
EP3906937A1 (en) 2021-11-10
EP3326643B1 (en) 2021-04-07
CA3121739A1 (en) 2011-06-09
NO2506868T3 (ru) 2018-04-14
EP3326643A1 (en) 2018-05-30
EP4382170A2 (en) 2024-06-12
NZ703153A (en) 2015-02-27
US20130108629A1 (en) 2013-05-02
AU2017268648B2 (en) 2019-01-31
EP2506868B1 (en) 2017-11-15
JP2018024706A (ja) 2018-02-15
US20160199455A1 (en) 2016-07-14
SI2506868T1 (en) 2018-04-30
SG10201907152YA (en) 2019-09-27
NZ600709A (en) 2015-01-30
KR101770849B1 (ko) 2017-09-05
PL2506868T3 (pl) 2018-06-29
US20190262429A1 (en) 2019-08-29
US11266720B2 (en) 2022-03-08
ME02964B (me) 2018-07-20
JP6062459B2 (ja) 2017-01-18
WO2011069164A3 (en) 2011-07-28
MX336830B (es) 2016-02-03
SG10201408049SA (en) 2015-02-27
JP2023071969A (ja) 2023-05-23
JP7244688B2 (ja) 2023-03-22
CY1119919T1 (el) 2018-06-27
AU2010325787A8 (en) 2012-07-19
AU2010325787A1 (en) 2012-07-12
IL220204A0 (en) 2012-07-31
JP5903048B2 (ja) 2016-04-13

Similar Documents

Publication Publication Date Title
EA201691109A1 (ru) Химерные и гибридные полипептиды фактора viii-fc и способы их применения
EA201291480A1 (ru) Фактор ix полипептиды и способы их использования
EA201490039A1 (ru) Химерные и гибридные полипептиды фактора viii и способы их применения
MX2019000643A (es) Receptores de antigenos quimericos y metodos de uso.
IN2014CN04586A (ru)
MX2011008262A (es) Espiroamidas sustituidas como moduladores de b1r:.
EA201492101A1 (ru) Антитела против fcrn
MX349630B (es) Alfa-amilasas.
CO6511271A2 (es) Compuestos de imidazopiridinil-aminopiridina sustituida
EA201891264A2 (ru) Антагонисты st2l и способы их применения
MX2013007853A (es) Polipeptidos que tienen actividad de celobiohidrolasa y polinucleotidos que codifican los mismos.
MX337919B (es) Polipeptidos que tienen actividad de celobiohidrolasa y polinucleotidos que codifican los mismos.
EA201400964A1 (ru) Cx3cr1-связывающие полипептиды
MX337913B (es) Polipeptidos que tienen actividad celobiohidrolasa y polinucleotidos que codifican los mismos.
MX2013004892A (es) Polipeptidos que tienen actividad de fosfolipasa c y polinucleotidos que codifican los mismos.
EA201100161A1 (ru) Производные хинуклидина карбоната и их медицинские композиции
IN2014CN03072A (ru)
EP2516624A4 (en) CELL LINE 3M
FI20115328A (fi) Uusia kutinaaseja, niiden tuottaminen ja käytöt
MX2011012623A (es) Construcciones de casb7439.
BR112016007618A2 (pt) métodos de síntese química de compostos de diaminofenotiazínio incluindo cloreto de metiltionínio (mtc)
EA202092566A1 (ru) Фактор ix полипептиды и способы их использования
EA201290145A1 (ru) Молекула нуклеиновой кислоты, кодирующая тритерпеноидсинтазу